EU/3/01/041: Orphan designation for the treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency

Recombinant human alpha-1 antitrypsin

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2008 on request of the sponsor.

On, 30 May 2001 orphan designation (EU/3/01/041) was granted by the European Commission to Bayer AG, Germany, recombinant human alpha-1 antitrypsin for the treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency.

The sponsorship was transferred to Talecris Biotherapeutics GmbH, Germany in March 2007.

Key facts

Active substance
Recombinant human alpha-1 antitrypsin
Intended use
Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency
Orphan designation status
Withdrawn
EU designation number
EU/3/01/041
Date of designation
30/05/2001
Sponsor
Talecris Biotherapeutics GmbH
Lyoner Str. 15
D-60528 Frankfurt am Main
Germany
Telephone: +49 69 66 05 93 401
Telefax: +49 69 66 05 93 110
E-mail: wolfgang.schulten@talecris.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating